NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense<
02 Sep 2009

Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense

Barcelona – September 1, 2009 – Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing.
02 Sep 2009

Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense

Barcelona – September 1, 2009 – Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing.
Ysios Capital Partners announces the first closing of the largest Spanish biotech fund at €67million<
15 Sep 2008

Ysios Capital Partners announces the first closing of the largest Spanish biotech fund at €67million

The fund will be invested in 10 to 12 biotechnology companies in the field of human health.
Raúl Martín-Ruiz joins Ysios Capital Partners as Investment Manager<
03 Sep 2008

Raúl Martín-Ruiz joins Ysios Capital Partners as Investment Manager

Main responsibilities of Martín-Ruiz will be to analyze and evaluate the feasibility of the target companies of the fund from a scientific and business point of view.
Paula Olazábal joins Ysios Capital Partners as investment manager<
22 Jul 2008

Paula Olazábal joins Ysios Capital Partners as investment manager

Her appointment comes along with the new stage of the venture capital firm specialized in biotech, which is preparing the first closing of Ysios BioFund I.
Ysios Capital Partners names Marc Casellas as Chief Financial Officer<
09 Jul 2008

Ysios Capital Partners names Marc Casellas as Chief Financial Officer

Ysios has created this position to manage the increased activity expected as the initial capital subscription of its first fund, Ysios BioFund I, draws to a close
Ysios Capital Partners announces the imminent first closing of the largest Spanish venture capital fund in the biotech sector<
10 Mar 2008

Ysios Capital Partners announces the imminent first closing of the largest Spanish venture capital fund in the biotech sector

The company anticipates a first closing of around EUR 60 million in brief.
20 Sep 2007

Ysios co-leads €27,2million Series B financing of stem cell company Cellerix

Barcelona, September 20, 2007. ‐ Cellerix, a biopharmaceutical company leader in the clinical development and production of innovative medicines based on adult stem cells, has closed an oversubscribed Series B financing round for €27.2M.
Ysios co-leads €27,2million Series B financing of stem cell company Cellerix<
20 Sep 2007

Ysios co-leads €27,2million Series B financing of stem cell company Cellerix

The round was led by two of the most experienced life science investors in Europe, LSP (Netherlands) and Ventech (France).
Ysios Capital Partners Starts Registration as an Independent Biotech Venture Capital Firm in Spain<
13 Sep 2007

Ysios Capital Partners Starts Registration as an Independent Biotech Venture Capital Firm in Spain

Ysios Capital Partners will be raising €65 million for their first fund, Ysios BioFund I.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.